Loading...

Sio Gene Therapies Inc.

SIOX•NASDAQ
HealthcareBiotechnology
$0.48
$0.09(22.63%)

Sio Gene Therapies Inc. (SIOX) Stock Overview

Explore Sio Gene Therapies Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for SIOXStats details for SIOX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for SIOXAnalyst Recommendations details for SIOX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

CEO

Mr. David W. Nassif J.D.

Employees

12

Headquarters

130 West 42nd Street, New York City, NY

Founded

2015

Frequently Asked Questions